Suchergebnisse - "Schmid, Peter"

PubPharm (633)

21

Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer : KEYNOTE-086 Exploratory Analysis

enthalten in: JCO precision oncology | 2023

von Loi, S. | Salgado, R. | Schmid, P. | +20

22

Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer : A Detailed Safety Analysis of the Randomized PARSIFAL Trial

enthalten in: The oncologist | 2023

von Di Cosimo, S. | Pérez-García, J. | Bellet, M. | +20

23

NEPTUNE : Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2023

von de Castro, G. | Rizvi, N. | Schmid, P. | +20

CommentIn: J Thorac Oncol. 2023 Jan;18(1):29-30. - PMID 36543434

24

Evaluation of triple negative breast cancer with heterogeneous immune infiltration

enthalten in: Frontiers in immunology | 2023

von Quintana, �. | Arenas, E. | Bernadó, C. | +10

25

Experimentelle Validierung von dreidimensionalen interaktiven Systemen in der Medizintechnik

Erschienen: Dissertation, Universität Stuttgart, 2023

Bericht / Institut für Konstruktionstechnik und Technisches Design, Universität Stuttgart - Nr. 715

von Schmid, P. | Maier, T.

26

Prognostic and predictive impact of gene expression in node‐positive early breast cancer patients receiving dose‐dense versus standard‐dose adjuvant chemotherapy

enthalten in: Molecular Oncology | 2023

von Reinisch, M. | Bruzas, S. | Gluz, O. | +12

27

New fossils ofAustralopithecus sedibareveal a nearly complete lower back

enthalten in: bioRxiv.org | 2022

von Williams, S. | Prang, T. | Meyer, M. | +13

28

Pembrolizumab in Triple-Negative Breast Cancer. Reply

enthalten in: The New England journal of medicine | 2022

von Cortes, J. | Zhou, X. | Schmid, P.

CommentOn: N Engl J Med. 2022 Oct 13;387(15):1435. - PMID 36239656

29

Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2022

von Rugo, H. | Bardia, A. | Marmé, F. | +13

CommentIn: J Clin Oncol. 2023 Feb 1;41(4):732-735. - PMID 36446052

30

ASTEFANIA : adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer

enthalten in: Future oncology (London, England) | 2022

von Hurvitz, S. | Bachelot, T. | Bianchini, G. | +13